

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

### Crisaborole for treating mild to moderate atopic dermatitis in people aged 2 years and older ID1195

#### Final matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• Pfizer (crisaborole)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action Against Allergy</li> <li>• Allergy UK</li> <li>• Changing Faces</li> <li>• Let's Face it</li> <li>• Action for Sick Children</li> <li>• Muslim Council of Britain</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• The National Eczema Society</li> <li>• National Children's Bureau</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of Paediatric Emergency Medicines</li> <li>• British Association for Accident and Emergency Medicine</li> <li>• British Association for Immediate Care</li> <li>• British Association of Dermatologists</li> <li>• British Contact Dermatitis Society</li> <li>• British Dermatological Nursing Group</li> <li>• British Geriatrics Society</li> <li>• British Society for Cutaneous Allergy</li> <li>• British Skin Foundation</li> <li>• British Trauma Society</li> <li>• Primary Care Dermatology Society</li> <li>• Royal College of Emergency Medicine</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Paediatrics &amp; Child Health</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• Allied Health Professionals Federation</li> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Confederation</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> <li>• Accord Healthcare (tacrolimus)</li> <li>• Accord UK (betamethasone valerate, hydrocortisone)</li> <li>• Alliance Pharmaceuticals (benzalkonium chloride, dimeticone, hydrocortisone, nystatin)</li> <li>• Aspire Pharma (fluticasone propionate)</li> <li>• Auden Mckenzie Pharma Division, a subsidiary of Actavis PLC (betamethasone valerate, mometasone furoate)</li> <li>• Boots Company PLC</li> </ul>

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Surgical Dressing Manufacturers Association</li> <li>• Tissue Viability Society</li> <li>• UK Clinical Pharmacy Association</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> <li>• NHS Cannock Chase CCG</li> <li>• NHS South Worcestershire CCG</li> <li>• Welsh Government</li> </ul>	<p>(hydrocortisone)</p> <ul style="list-style-type: none"> <li>• Dermal Laboratories (hydrocortisone)</li> <li>• Ennogen Healthcare (clobetasone butyrate, nystatin, oxytetracycline calcium)</li> <li>• Galderma UK (hydrocortisone)</li> <li>• Generics UK T/A Mylan (betamethasone valerate, mometasone furoate)</li> <li>• GlaxoSmithKline Consumer Healthcare (betamethasone valerate, clobetasone butyrate, fluticasone propionate, hydrocortisone)</li> <li>• <u>Glenmark Pharmaceuticals Europe</u> (mometasone furoate)</li> <li>• Intrapharm Laboratories (hydrocortisone, oxytetracycline hydrochloride)</li> <li>• Janssen-Cilag (hydrocortisone)</li> <li>• Karo Pharma AB (hydrocortisone)</li> <li>• Leo Laboratories (betamethasone valerate, fusidic acid, hydrocortisone, tacrolimus)</li> <li>• Marlborough Pharmaceuticals (hydrocortisone)</li> <li>• Merck Sharp &amp; Dohme (betamethasone dipropionate, mometasone furoate)</li> <li>• Mylan (pimecrolimus)</li> <li>• <u>Pinewood Healthcare</u> (hydrocortisone)</li> <li>• Reckitt Benckiser Healthcare (hydrocortisone)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• British Epidermo-Epidemiology Society</li> <li>• Centre of Evidence-based Dermatology, University of Nottingham</li> <li>• Cochrane Skin Group</li> <li>• Genomics England</li> <li>• MRC Clinical Trials Unit</li> <li>• National Institute for Health Research</li> <li>• Skin Research Centre</li> <li>• Skin Treatment &amp; Research Trust</li> </ul>

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
	<u>Associated Public Health groups</u> <ul style="list-style-type: none"> <li>• Public Health England</li> <li>• Public Health Wales</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

## Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

## Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.